Glaukos Corporation is an ophthalmic pharmaceutical and medical technology company. It develops novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders and retinal disease. Its product candidates include Micro-Invasive Glaucoma Surgery products that involve the insertion of a micro-scale device designed to reduce intraocular pressure (IOP) by restoring the natural aqueous humor outflow pathways for patients suffering from glaucoma and procedural pharmaceuticals based on an intracameral drug delivery technology designed to reduce IOP by delivering therapeutic levels of glaucoma medication from inside the eye over an extended period of time. Its products include transdermal pharmaceuticals that are applied to the eyelid and designed to treat glaucoma, dry eye, presbyopia and other ocular surface diseases and disorders and micro-invasive, bio-erodible sustained release drug delivery implants to improve the vision of patients.
企業コードGKOS
会社名Glaukos Corp
上場日Jun 25, 2015
最高経営責任者「CEO」Mr. Thomas William Burns
従業員数995
証券種類Ordinary Share
決算期末Jun 25
本社所在地1 Glaukos Way
都市ALISO VIEJO
証券取引所NYSE Consolidated
国United States of America
郵便番号92656
電話番号19493679600
ウェブサイトhttps://www.glaukos.com
企業コードGKOS
上場日Jun 25, 2015
最高経営責任者「CEO」Mr. Thomas William Burns
過去5年間の配当金総支払額は
0.00
米ドルである。

データなし